We focus on therapies for the treatment of bronchopulmonary disease
This section of the website provides information for existing and potential investors in Vectura Group plc including financial reports, an interactive share price chart and updates on our latest news.
Vectura's focused application of technology, know-how and expertise has demonstrated that the potential for new inhaled pharmaceuticals with real therapeutic and commercial value can be realised.
Jefferies Healthcare Conference, London, 20 November 2013
Vectura Group plc interim results for the six months ending 30 September 2013
Annual Report and Accounts for Year Ended 31 March 2013
19 Nov 2013
Vectura Group plc - Interim Results for the six months ended 30 September 2013
14 Nov 2013
Bruno Angelici joins the Board of Vectura
30 Sep 2013
Vectura and UCB to collaborate and share expertise in severe inflammatory disease
Share price table
Stay informed Register to our news alert and receive latest updates on news and events
For general enquiries, call us on +44 (0)1249 667700. For more specific enquiries, visit Contact us
Most computers will open PDF documents automatically, but you may need to download Adobe Reader.